Valuation: Insmed Incorporated

Market Cap 24.27B 21.56B 20.12B 18.34B 34.59B 2,333B 34.91B 244B 94.37B 1,193B 91.11B 89.13B 3,827B P/E 2026 *
-68.2x
P/E 2027 * 160x
Enterprise Value 23.63B 21B 19.6B 17.86B 33.69B 2,272B 34.01B 237B 91.91B 1,162B 88.74B 86.81B 3,728B EV / Sales 2026 *
13.1x
EV / Sales 2027 * 8.04x
Free-Float
99.49%
Yield 2026 *
-
Yield 2027 * -
1 day+2.33%
1 week-5.69%
Current month-2.65%
1 month-12.28%
3 months-0.43%
6 months-31.59%
Current year-36.15%
1 week 105.68
Extreme 105.68
119.32
1 month 105.68
Extreme 105.68
130.83
Current year 90.39
Extreme 90.39
186.19
1 year 90.39
Extreme 90.39
212.75
3 years 21.92
Extreme 21.92
212.75
5 years 16.04
Extreme 16.04
212.75
10 years 10.21
Extreme 10.21
212.75
Manager TitleAgeSince
Chief Executive Officer 57 2012-09-09
Director of Finance/CFO 45 2020-01-30
Chief Tech/Sci/R&D Officer 62 2019-12-18
Director TitleAgeSince
Chairman 75 2009-06-15
Chairman 57 2018-11-07
Director/Board Member 72 2014-05-28
Date Insider Type Main position Quantity % Market Cap. Importance
9/9/26 Sell

Director

-25,000 0.0114%
8/17/26 Sell

Director

-5,000 0.0023%
8/10/26 Exercice

Chief Operating Officer

719,550 0.3320%
Change 5-day change 1-year change 3-year change Capi.($)
+2.33%-5.69%-29.29%+356.91% 24.27B
+4.16%+3.04%+49.37%+94.17% 74.16B
-3.11%-3.53%+20.19%+81.44% 57.39B
+0.89%-0.63%+2.17%+36.19% 47.64B
+0.36%+0.81%+342.39%+742.40% 44.29B
-0.96%-4.50%+24.96%+35.38% 42.5B
-0.20%-0.77%+4.13%+105.50% 40.71B
-0.54%+2.93%+9.31%+50.41% 30.97B
-2.68%+2.92%+29.33%+22.72% 28.53B
+0.05%-1.64%-8.14%-11.37% 24.34B
Average +0.03%-1.10%+44.44%+151.38% 41.48B
Weighted average by Cap. +0.25%-1.12%+51.91%+151.05%

Financials

2026 *2027 *
Net sales 1.81B 1.61B 1.5B 1.37B 2.58B 174B 2.6B 18.15B 7.03B 88.86B 6.79B 6.64B 285B 2.88B 2.56B 2.38B 2.17B 4.1B 276B 4.14B 28.86B 11.18B 141B 10.8B 10.56B 454B
Net income -350M -311M -290M -264M -499M -33.63B -503M -3.51B -1.36B -17.19B -1.31B -1.28B -55.17B 182M 161M 151M 137M 259M 17.46B 261M 1.82B 706M 8.93B 682M 667M 28.65B
Net Debt -632M -561M -524M -478M -901M -60.74B -909M -6.34B -2.46B -31.05B -2.37B -2.32B -99.65B -1.16B -1.03B -959M -874M -1.65B -111B -1.66B -11.61B -4.5B -56.84B -4.34B -4.25B -182B
Logo Insmed Incorporated
Insmed Incorporated is a global biopharmaceutical company. It is advancing a diverse range of approved and mid- to late-stage investigational medicines and drug discovery. Its advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. Its pre-clinical research programs encompass a range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Its first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib, TPIP, and INS1201 and pre-clinical research programs. Its INS1148 is an investigational monoclonal antibody.
Employees
1,664
Date Price Change Volume
26-10-02 US$111.12 +2.33% 4,136,266
26-10-01 US$108.59 -4.86% 2,646,512
26-09-30 US$114.14 -1.29% 2,870,338
26-09-29 US$115.63 -1.73% 1,668,367
26-09-28 US$117.67 -0.14% 1,744,370
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
111.12USD
Average target price
197.74USD
Spread / Average Target
+77.95%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INSM Stock